David G. Warnock

22.8k total citations · 3 hit papers
223 papers, 16.1k citations indexed

About

David G. Warnock is a scholar working on Molecular Biology, Physiology and Nephrology. According to data from OpenAlex, David G. Warnock has authored 223 papers receiving a total of 16.1k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 82 papers in Physiology and 37 papers in Nephrology. Recurrent topics in David G. Warnock's work include Ion Transport and Channel Regulation (69 papers), Lysosomal Storage Disorders Research (68 papers) and Ion channel regulation and function (28 papers). David G. Warnock is often cited by papers focused on Ion Transport and Channel Regulation (69 papers), Lysosomal Storage Disorders Research (68 papers) and Ion channel regulation and function (28 papers). David G. Warnock collaborates with scholars based in United States, France and United Kingdom. David G. Warnock's co-authors include Ravindra L. Mehta, Bruce A. Molitoris, Claudio Ronco, Adeera Levin, John A. Kellum, Sudhir V. Shah, Christoph Wanner, Stephen Waldek, William R. Wilcox and Jill Eveloff and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David G. Warnock

220 papers receiving 15.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

2007 5.2k citations Ravindra L. Mehta, Bruce A. Molitoris et al. profile →
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations David G. Warnock et al. profile →
Acute Kidney Injury and Mortality in Hospitalized Patients

2012 377 citations Glenn M. Chertow, David G. Warnock et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David G. Warnock United States	57	5.8k	4.2k	3.9k	3.0k	2.5k	223	16.1k
Hermann Haller Germany	80	4.4k 0.8×	1.9k 0.5×	7.0k 1.8×	2.0k 0.7×	4.8k 1.9×	454	23.0k
Masaomi Nangaku Japan	82	8.4k 1.4×	2.0k 0.5×	6.9k 1.8×	1.9k 0.6×	2.4k 1.0×	712	24.1k
Danilo Fliser Germany	75	6.6k 1.1×	2.3k 0.6×	4.0k 1.0×	2.0k 0.7×	4.3k 1.7×	301	18.6k
David A. Roth United States	47	6.6k 1.1×	1.3k 0.3×	2.3k 0.6×	2.0k 0.7×	4.1k 1.7×	212	20.6k
Walter Zidek Germany	53	2.7k 0.5×	2.0k 0.5×	2.8k 0.7×	1.2k 0.4×	4.1k 1.7×	445	13.1k
Rijk O. B. Gans Netherlands	62	3.0k 0.5×	2.3k 0.5×	2.3k 0.6×	1.5k 0.5×	3.1k 1.3×	358	15.3k
Olof Heimbürger Sweden	62	10.6k 1.8×	3.9k 0.9×	1.7k 0.4×	1.9k 0.6×	1.5k 0.6×	307	17.1k
Thomas H. Hostetter United States	68	10.7k 1.8×	2.6k 0.6×	3.9k 1.0×	1.2k 0.4×	3.6k 1.5×	187	20.1k
Karl A. Nath United States	72	3.8k 0.7×	1.7k 0.4×	7.0k 1.8×	752 0.3×	1.1k 0.5×	219	15.7k
Enyu Imai Japan	61	7.4k 1.3×	1.5k 0.4×	4.8k 1.2×	1.6k 0.6×	3.6k 1.5×	324	18.7k

Countries citing papers authored by David G. Warnock

Since Specialization

Citations

This map shows the geographic impact of David G. Warnock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Warnock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Warnock more than expected).

Fields of papers citing papers by David G. Warnock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Warnock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Warnock. The network helps show where David G. Warnock may publish in the future.

Co-authorship network of co-authors of David G. Warnock

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Warnock. A scholar is included among the top collaborators of David G. Warnock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Warnock. David G. Warnock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fatima, Huma, et al.. (2024). The underdiagnosed kidney burden of Fabry disease in females. 8(4). 394–405. 1 indexed citations

Banikazemi, Maryam, Jan Bultas, Stephen Waldek, et al.. (2020). Agalsidase-Beta Therapy for Advanced Fabry Disease. Annals of Internal Medicine. 146(2). 1 indexed citations

Germain, Dominique P., João Paulo Oliveira, Daniel G. Bichet, et al.. (2020). Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup. Journal of Medical Genetics. 57(8). 542–551. 51 indexed citations

Swaminathan, Madhav, Mark Stafford‐Smith, Glenn M. Chertow, et al.. (2017). Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. Journal of the American Society of Nephrology. 29(1). 260–267. 95 indexed citations

Warnock, David G., Kristina Kusche‐Vihrog, Antoine Tarjus, et al.. (2014). Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells. Nature Reviews Nephrology. 10(3). 146–157. 89 indexed citations

Nelson, Michael, et al.. (2014). Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Acta Neuropathologica Communications. 2(1). 20–20. 59 indexed citations

O’Riordan, Thomas G., Peter Hodsman, John H. Ansede, et al.. (2013). Acute Hyperkalemia Associated with Inhalation of a Potent ENaC Antagonist: Phase 1 Trial of GS-9411. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(3). 200–208. 45 indexed citations

Warnock, David G., Sudarshan Hebbar, Joanne M. Bargman, et al.. (2012). Prospective Safety Study of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus, End-Stage Renal Disease and Peritoneal Dialysis. Contributions to nephrology. 178. 157–163. 4 indexed citations

Wilcox, William R., Gabor E. Linthorst, Dominique P. Germain, et al.. (2011). Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Molecular Genetics and Metabolism. 105(3). 443–449. 57 indexed citations

10.

Bertocchio, Jean‐Philippe, David G. Warnock, & Frédéric Jaisser. (2011). Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International. 79(10). 1051–1060. 113 indexed citations

11.

Muntner, Paul, Suzanne E. Judd, William McClellan, et al.. (2011). Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Nephrology Dialysis Transplantation. 27(1). 166–173. 29 indexed citations

12.

Waldek, Stephen, Edward H. Giannini, Atul Mehta, et al.. (2010). 140. A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism. 99(2). S37–S37. 4 indexed citations

13.

Warnock, David G.. (1999). The epithelial sodium channel in hypertension. Current Hypertension Reports. 1(2). 158–163. 12 indexed citations

14.

Markovitz, Jerome H., Diane C. Tucker, Cora E. Lewis, Paul W. Sanders, & David G. Warnock. (1998). Inverse Relationship of Urinary Cyclic GMP to Blood Pressure Reactivity in the CARDIA Study. Psychosomatic Medicine. 60(3). 319–326. 5 indexed citations

15.

DuBose, Thomas D., David G. Warnock, Ravindra L. Mehta, et al.. (1997). Acute renal failure in the 21st century: Recommendations for management and outcomes assessment. American Journal of Kidney Diseases. 29(5). 793–799. 72 indexed citations

16.

Watson, Bracie, Norma J. Nowak, Angela D. Myracle, Thomas B. Shows, & David G. Warnock. (1997). The Human Angiotensinase C Gene (HUMPCP) Maps to 11q14 within 700 kb of D11S901: A Candidate Gene for Essential Hypertension. Genomics. 44(3). 365–367. 22 indexed citations

17.

Lewis, Jennifer L., T. Serikawa, & David G. Warnock. (1993). Chromosomal Localization of Angiotensin II Type 1 Receptor Isoforms in the Rat. Biochemical and Biophysical Research Communications. 194(2). 677–682. 30 indexed citations

18.

Burckhardt, Gerhard & David G. Warnock. (1990). Mechanism of H+ secretion in the proximal convoluted tubule.. PubMed. 10(2). 93–103. 7 indexed citations

19.

Flaherty, John F., et al.. (1989). Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clinical Pharmacology & Therapeutics. 45(3). 321–327. 21 indexed citations

20.

Warnock, David G.. (1988). Uremic acidosis. Kidney International. 34(2). 278–287. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact